As biologics programs advance toward commercialization, cell line development and manufacturing decisions are being made earlier and with far less room for error. What may seem like manageable challenges during early clone selection and development can surface later as product variability, cell line instability, technology transfer complications, and scalability limitations that threaten clinical timelines and commercial readiness.
Successfully navigating these complexities requires a clear understanding of how cell line development, process development, GMP manufacturing, scale-up, and CDMO strategy work together throughout the product lifecycle. In this edition of the Outsourced Pharma Capabilities Update (OPCU), explore how leading biologics CDMOs are helping sponsors establish stable, high-producing cell lines, reduce downstream risk, simplify technology transfer, and build manufacturing strategies that support long-term success. Watch the presentations below to learn how different development and outsourcing approaches can impact program outcomes from early development through launch.
Recent Sessions Available On-Demand
Cell Therapy & Cell Line Development – July 2026
ADCs And Microbial Development & Manufacturing – July 2026
Upcoming OPCU Topics & Times
Fill/Finish | 9/1/2026, AM Session
ADCs | 9/11/2026, AM Session
AI Innovation in Drug Development & Manufacturing | 9/29/2026, AM Session
Viral Vectors | 9/29/2026, PM Session
mRNA | 9/30/2026, AM Session
Packaging, Labeling, & Logistics Services | 9/30/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
